ZAG
0.047
56.7%
SRN
0.001
-50%
RAN
0.003
50%
GEN
0.012
-45.5%
CXL
0.675
45.2%
C7A
0.002
-33.3%
TDO
0.16
39.1%
RLG
0.003
-25%
1AD
0.004
33.3%
TMKDD
0.115
-23.3%
CPN
0.16
28%
VBS
0.195
-22%
SCP
0.125
27.6%
QXR
0.004
-20%
TGH
0.028
27.3%
RKB
0.004
-20%
MBK
0.019
26.7%
ENL
0.019
-17.4%
RMX
0.038
26.7%
AMS
0.03
-16.7%
ILA
0.525
23.5%
ALM
0.006
-14.3%
ATR
0.855
22.1%
SQX
0.15
-14.3%
VTX
0.265
20.5%
GCM
0.013
-13.3%
AKN
0.006
20%
GLA
0.013
-13.3%
AVL
0.012
20%
SHP
0.026
-13.3%
BLU
0.006
20%
DKM
0.165
-13.2%
VAR
0.006
20%
MRZ
0.3
-13%
SP8
0.013
18.2%
SCN
0.027
-12.9%
GDM
0.35
16.7%
ITM
0.055
-12.7%
ZEU
0.014
16.7%
NFL
0.14
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759